Deutsche Bank AG Takes $10.32 Million Position in Cogent Biosciences, Inc. $COGT

Key Points

• Deutsche Bank acquired a new 266,584-share stake in Cogent Biosciences during the second quarter, valued at approximately $10.32 million and representing about 0.16% of the company.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $49.40 price target; several firms raised targets to $52–$55, although HC Wainwright lowered its 2026 EPS forecasts to reflect larger expected losses.
• Cogent reported a quarterly loss of $0.52 per share, slightly better than estimates, while its lead oral CSF1R inhibitor advances through early-stage trials targeting solid tumors.

Deutsche Bank AG acquired a new stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 266,584 shares of the technology company's stock, valued at approximately $10,317,000. Deutsche Bank AG owned approximately 0.16% of Cogent Biosciences as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of COGT. EverSource Wealth Advisors LLC increased its holdings in Cogent Biosciences by 1,164.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 708 shares of the technology company's stock worth $25,000 after purchasing an additional 652 shares in the last quarter. J.Safra Asset Management Corp bought a new position in Cogent Biosciences in the second quarter valued at about $27,000. Osaic Holdings Inc. boosted its stake in shares of Cogent Biosciences by 41.4% during the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company's stock valued at $33,000 after purchasing an additional 1,333 shares in the last quarter. Strs Ohio acquired a new stake in shares of Cogent Biosciences during the first quarter valued at about $36,000. Finally, Global Retirement Partners LLC bought a new stake in shares of Cogent Biosciences during the fourth quarter worth about $37,000.

Key Cogent Biosciences News

Here are the key news stories impacting Cogent Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $55 price objective for COGT, signaling confidence in Cogent Biosciences’ longer-term growth prospects. HC Wainwright analyst coverage
• Positive Sentiment: The analyst expects losses to narrow significantly in 2027, forecasting quarterly EPS of $(0.50), $(0.38), $(0.26), and $(0.15), resulting in a full-year loss of $(1.28). The improving trajectory may support the stock’s valuation if Cogent’s pipeline advances as expected. Cogent Biosciences 2027 earnings estimates
• Neutral Sentiment: HC Wainwright initiated its 2027 estimates, including a $(1.28) full-year EPS forecast. These projections provide new expectations for investors but do not represent a change to the company’s operating results. Cogent Biosciences analyst estimates
• Negative Sentiment: HC Wainwright reduced its 2026 EPS forecasts, lowering Q3 estimates to $(0.59) from $(0.56), Q4 estimates to $(0.62) from $(0.57), and full-year estimates to $(2.37) from $(2.21). The revisions indicate higher expected losses in the near term and could limit upside despite the bullish rating. Cogent Biosciences 2026 earnings estimate revisions

Cogent Biosciences Stock Performance

NASDAQ:COGT opened at $36.73 on Monday. Cogent Biosciences, Inc. has a 52 week low of $11.60 and a 52 week high of $43.73. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.57 and a current ratio of 13.57. The firm's fifty day moving average is $38.49 and its 200-day moving average is $36.62. The firm has a market cap of $6.37 billion, a P/E ratio of -17.00 and a beta of 0.38.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its earnings results on Monday, August 10th. The technology company reported ($0.52) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.03. Equities analysts expect that Cogent Biosciences, Inc. will post -2.24 earnings per share for the current year.

Wall Street Analyst Weigh In

COGT has been the subject of several recent research reports. Wedbush reaffirmed an "outperform" rating and issued a $55.00 price objective on shares of Cogent Biosciences in a research note on Friday, May 29th. Piper Sandler lifted their target price on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an "overweight" rating in a research report on Monday, August 17th. Guggenheim boosted their target price on shares of Cogent Biosciences from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Cogent Biosciences in a research report on Wednesday, July 8th. Finally, Wall Street Zen upgraded shares of Cogent Biosciences from a "sell" rating to a "hold" rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source